Palbociklib
Palbociklib
Klass : B
Visa all info
Skriv ut
Kontakta oss
Physicians' Desk Reference. http://www.pdr.net. [cited 2018-12-17].
Fass.se [cited 2018-12-06].
Flaherty KT, Lorusso PM, Demichele A, Abramson VG, Courtney R, Randolph SS et al. Phase I, dose-escalation trial of the oral cyclin-dependent kinase 4/6 inhibitor PD 0332991, administered using a 21-day schedule in patients with advanced cancer. Clin Cancer Res. 2012;18(2):568-76.
Sun W, O'Dwyer PJ, Finn RS, Ruiz-Garcia A, Shapiro GI, Schwartz GK et al. Characterization of Neutropenia in Advanced Cancer Patients Following Palbociclib Treatment Using a Population Pharmacokinetic-Pharmacodynamic Modeling and Simulation Approach. J Clin Pharmacol. 2017;57(9):1159-1173.
Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2017 [cited 2018-12-17.]
- Physicians' Desk Reference. http://www.pdr.net. [cited 2018-12-17].
- Fass.se [cited 2018-12-06].
- Flaherty KT, Lorusso PM, Demichele A, Abramson VG, Courtney R, Randolph SS et al. Phase I, dose-escalation trial of the oral cyclin-dependent kinase 4/6 inhibitor PD 0332991, administered using a 21-day schedule in patients with advanced cancer. Clin Cancer Res. 2012;18(2):568-76.
- Sun W, O'Dwyer PJ, Finn RS, Ruiz-Garcia A, Shapiro GI, Schwartz GK et al. Characterization of Neutropenia in Advanced Cancer Patients Following Palbociclib Treatment Using a Population Pharmacokinetic-Pharmacodynamic Modeling and Simulation Approach. J Clin Pharmacol. 2017;57(9):1159-1173.
- Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2017 [cited 2018-12-17.]